Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tailored Temozolomide in Poor Risk AML
NCT00611247Phase 2Completed
- Start
- Dec 2007
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of temozolomide in acute myeloid leukemia (AML) (2 arms). Primary endpoint: Response Rate (CR + CRi + LFS) at 2 months. Started Dec 2007; status: completed.
02
Drugs
temozolomide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00611247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00611247.